Clinical trials on Acute Myeloid Leukemia

  • CT-EU-00116217

    Testing a New Three-Drug Combination for advanced myeloid malignancies

    This is a phase 1 clinical trial testing a new combination of three drugs – navitoclax, venetoclax, and decitabine – for treating advanced myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, and myelofibrosis accelerated phase. The main goal is to find the safest and most effective dose of this drug combination. Around 36 people are expected to participate.

    During the trial, you will receive the study treatment regimen as long as it is working for you. The researchers will closely monitor your health through blood tests and bone marrow biopsies to assess how well the treatment is working and check for any side effects. The observation period for evaluating potential dose-limiting toxicities is the first 28 days of treatment.

    • decitabine
    • Navitoclax
    • Venetoclax
  • Oral Azacitidine Maintenance Therapy After CPX-351 for Acute Myeloid Leukemia

    This clinical trial is studying the use of an oral medication called azacitidine as a maintenance treatment for patients with acute myeloid leukemia (AML) who have achieved remission after receiving the chemotherapy drug CPX-351. AML is a type of blood cancer that can develop after receiving chemotherapy or radiation for another disease (called therapy-related AML or t-AML) or can arise from a pre-existing blood disorder (AML with myelodysplasia-related changes or AML-MRC).

    The study aims to see if taking oral azacitidine after achieving remission with CPX-351 can help improve overall survival in patients with these types of AML, as well as in patients with de novo AML (AML that develops without any known cause). Oral azacitidine has been approved by the FDA for use in AML patients who cannot receive intensive curative therapy like a stem cell transplant, but there is limited data on its effectiveness when used specifically after CPX-351 treatment.

    The trial will evaluate how long patients live after starting oral azacitidine maintenance, with survival being measured from the first dose up to 60 months. The safety of long-term oral azacitidine use will also be studied. Patients interested in this trial should speak with their doctor about the potential benefits and risks of participating.